JJ, I welcome your interest in biotech valuation. I agree that PDLI and MLNM are promising companies, but I suggest a little deeper look into HGSI's patent estate, and valuation. In particular, I would use a high discount rate in valuing HGSI because there are many potential challenges to their patents.
FWIW, Rick Harmon is not a "Harvard dip". If he "dips" it is from some post-graduate experience far away from Boston. Also, some of our best contributors are Harvard alums, but they can defend their own crimson souls without my help. BTW, if you're going to invest in biotechnology, you need to find out what has happened at Harvard and how that has powered so many companies. Look up Stuart Schreiber, or Vicki Sato, or read Barry Werth's book.
I emphasize what Peter said -- not every company that grabs Rick's attention goes to the moon (though they often do); but when Rick has reservations about a company, you should listen very, very closely. "Infallible" is too strong a word, but not by much.
This is my opinion only, but I've been here a very long time and watch every day. |
